HHS Leadership Shakeup
Trump Nominates Chris Klomp as HHS Deputy to Drive Healthcare Reforms and Lower Drug Costs
Key Points
Klomp’s role expanded beyond Medicare: since April 2025 he has been overseeing HHS operations as a senior advisor to RFK Jr. in addition to his Medicare director duties, indicating increased influence in agency leadership ahead of the deputy secretary nomination.
He personally led searches for top public health posts, including candidates to lead the CDC and the surgeon general’s office, illustrating his involvement in shaping key health leadership appointments.
Trump tied Klomp to major price-reduction efforts, including support for a most-favored-nation drug pricing policy and claims that drug prices have fallen significantly under his leadership.
Financial markets reflected cautious reception of the nomination, with Polymarket showing no immediate move in the 2028 GOP nomination odds after the report, indicating a perception of the appointment as a routine personnel move rather than a policy pivot.
President Donald Trump nominated Chris Klomp as deputy secretary of the Department of Health and Human Services on June 25, calling him "a potential STAR" in a post that has sat empty since February. Fox News reported the announcement was made alongside HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz.
Klomp currently serves as Medicare director and deputy administrator of the Centers for Medicare & Medicaid Services. The role he is nominated for is the number-two job at HHS, which oversees a budget of roughly $1.86 trillion, according to Fierce Healthcare.
Klomp's Quiet Rise to the Top of HHS
Klomp was appointed Medicare director on January 20, 2025. By April 2025, his role grew significantly. He became a senior adviser to RFK Jr. and took over day-to-day operations of HHS, according to The Epoch Times. That put him in charge of one of the largest agencies in the federal government well before his formal nomination.
He also led the search for leaders at the CDC and the surgeon general's office, personally vetting candidates for those key public health posts. Kennedy praised Klomp as "the operational partner I need to turn health policy into national reality." Trump went further, saying Klomp is "the engine room of our health revolution."
Drug Pricing Is Klomp's Central Mission
Trump tied the nomination directly to drug costs. He claimed prices for top-tier generic drugs fell 12% under Klomp's watch at Medicare, though independent analysts at Kaiser Health News put the real figure closer to 4% when adjusted for inflation. Either way, the administration is betting on Klomp to push these numbers further.
The centerpiece of that effort is a "most-favored-nation" drug pricing policy. The idea is simple: tie what the U.S. pays for drugs to the lower prices paid in other developed countries. Trump tried this in his first term but courts blocked it. By putting Klomp — a Medicare law specialist — in the deputy role, the administration signals a more legally careful second attempt, Fox News reported.
Senate Faces a Smooth but Watched Confirmation
Republicans hold 53 Senate seats. Klomp is expected to win confirmation with at least 55 votes, with some moderate Democratic support possible. Fierce Healthcare noted the deputy secretary post has been vacant since February, making quick confirmation a priority for the administration.
Democrats are not standing aside quietly. Senator Patty Murray said, "We will be scrutinizing Mr. Klomp's role in the potential dismantling of our public health surveillance systems." His power to finalize CDC and surgeon general picks — and likely install loyalists to the MAHA agenda — is a key concern for critics.
Markets See a Technocrat, Not a Pivot
Financial markets barely reacted. Polymarket showed no shift in 2028 GOP nomination odds after the news broke. Analysts described Klomp as a "known quantity" — a policy expert who can stabilize, rather than inflame, the more disruptive parts of the Make America Healthy Again movement.
Industry outlets like BioPharma Dive see Klomp differently — as a serious threat to the pharmaceutical status quo. Unlike past political appointees, he knows the specific levers of Medicare law. That makes him harder to outmaneuver in court or in contract negotiations with drug companies, according to Fox News.
Sentiment
Mostly NegativePublishers
11
Articles
24
Reach
35
